Sonnet BioTherapeutics, Inc.

As experts in cytokine biology, our clinical stage pipeline comprises five cytokine-derived therapeutic candidates, with our lead proprietary compound, SON-1010, in Phase 1 development. Closely following are SON-080, in Phase 1b/2a development, and three other candidates undergoing preclinical study. Sonnet’s proprietary FHAB™ (Fully Human Albumin Binding) technology enables the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms. The FHAB™ platform utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitchhikes” on human serum albumin (HSA) for transport to target tissues. Our internal focus is immune oncology, however, we believe our technology is suited for drug development across the spectrum of human disease. Sonnet’s FHAB construct attaches to albumin in the bloodstream, which significantly enhances the pharmacokinetics of the active drug substance. It also naturally accumulates at inflammation sites, including tumors, thereby potentiating delivery to target tissues. Our platform has demonstrated a tenfold increase in half-life and a greater-than-thirtyfold increase in efficacy as compared to recombinant interleukins without FHAB in preclinical studies. We believe the versatile platform can generate a large immune oncology pipeline, including combinations with a variety of biologic drugs. The Sonnet platform is differentiated in that FHAB utilizes a fully human sequence with a human glycosylation profile that can be manufactured using a standard CHO process. (NASDAQ: SONN)